ArticleFrontiers in medicine2025
Comparison of the efficacy and safety of super-selective and selective transcatheter arterial embolization in non-variceal gastrointestinal bleeding.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of empiric transcatheter arterial embolization for acute arterial upper gastrointestinal bleeding: A tertiary-care, single-center experience.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vascular interventional therapy (TAE) is an effective treatment for most abdominal organ hemorrhages, especially for non-variceal gastrointestinal bleeding (NVGIB) unresponsive to endoscopy. While selective and super selective embolization are two key interventional hemostasis methods, research on their application in total gastrointestinal bleeding is limited. This study compares these two techniques to assess their safety in non-variceal gastrointestinal bleeding hemostasis. Methods: We conducted a retrospective study on patients with NVGIB who received vascular interventional therapy from August 2014 to October 2024, comparing the clinical characteristics and outcomes of patients with selective or super-selective embolization. The primary outcome was clinical success, and secondary outcomes included technical success, rebleeding (overall and within 3 days), transfusion requirements, need for additional therapies, complications, and mortality. Results: A total of 116 patients with NVGIB who received vascular interventional therapy were included. Among the 88 patients with non-variceal upper gastrointestinal bleeding (NVUGIB), 48 and 40 were treated with super-selective and selective embolization, respectively. Gastroduodenal artery was the most common embolized vessel in both groups. All cases achieved technical success. 85.42% of the super-selective embolization group achieved clinical success, and 70.00% of the selective embolization group achieved clinical success ( Conclusion: For refractory NVUGIB, super-selective TAE compared to selective TAE reduces early rebleeding. Decision-making should prioritize patient transfusion needs, which was the sole independent predictor of rebleeding. The embolization strategy for LGIB should carefully consider the choice of embolic material and the inherent risk of intestinal ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.